Coya Therapeutics, Inc. Common Stock Total Liabilities
Coya Therapeutics, Inc. Common Stock total liabilities. Based on the latest financial reports, Coya Therapeutics, Inc. Common Stock (COYA) has total liabilities worth $4.03 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Coya Therapeutics, Inc. Common Stock (COYA) defensive interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Coya Therapeutics, Inc. Common Stock (2020–2025)
Total liabilities of Coya Therapeutics, Inc. Common Stock from 2020 to 2025. This chart illustrates how Coya Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Coya Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Coya Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eco World International Bhd
KLSE:5283
|
Malaysia | RM217.79 Million |
|
Country View Bhd
KLSE:5049
|
Malaysia | RM166.76 Million |
|
Talga Group Ltd
AU:TLG
|
Australia | AU$17.10 Million |
|
Act Co Ltd
KQ:138360
|
Korea | ₩43.97 Billion |
|
Altenergy Acquisition Corp
NASDAQ:AEAE
|
USA | $21.86 Million |
|
Technology & Telecommunication
NASDAQ:TETE
|
USA | $10.52 Million |
|
kenturn Nano Tec Co Ltd
TWO:4561
|
Taiwan | NT$859.47 Million |
|
Zhulian Corporation Bhd
KLSE:5131
|
Malaysia | RM32.93 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Coya Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Coya Therapeutics, Inc. Common Stock (COYA) total assets.
Liquidity & Leverage Metrics
Coya Therapeutics, Inc. Common Stock Total Liabilities Ratios Explained
Coya Therapeutics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Coya Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Coya Therapeutics, Inc. Common Stock (2020–2025)
The table below shows the annual total liabilities of Coya Therapeutics, Inc. Common Stock from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $6.92 Million | +45.12% |
| 2024-12-31 | $4.77 Million | -15.23% |
| 2023-12-31 | $5.63 Million | -66.49% |
| 2022-12-31 | $16.79 Million | +1361.98% |
| 2021-12-31 | $1.15 Million | +156.84% |
| 2020-12-31 | $447.12K | -- |
About Coya Therapeutics, Inc. Common Stock
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneou… Read more